Day One Biopharmaceuticals Inc (OQ:DAWN)

Business Focus: Biotechnology & Medical Research

Feb 26, 2024 04:30 pm ET
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Jan 17, 2024 08:00 am ET
Day One Announces Two New Appointments to Board of Directors
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Dec 19, 2023 08:00 am ET
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Nov 17, 2023 07:00 am ET
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Nov 14, 2023 08:00 am ET
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Nov 11, 2023 07:52 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) (“Day One”) on behalf of the company’s investors. Since February 2023, shares of Day One’s common stock have declined in value from a trading price...
Nov 07, 2023 12:16 am ET
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Day One Biopharmaceuticals, Inc.; Urges Day One Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Day One’s board of directors has violated its...
Nov 06, 2023 04:30 pm ET
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Oct 30, 2023 08:00 am ET
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Sep 11, 2023 08:30 am ET
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Aug 16, 2023 08:00 am ET
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into an...
Aug 07, 2023 04:30 pm ET
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Jun 12, 2023 08:00 am ET
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the closing on June...
Jun 08, 2023 07:00 am ET
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
SYDNEY, June 8, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting the University of Sydney on a molecularly-guided phase II clinical study to examine paxalisib in adult patients with recurrent/progressive isocitrate dehydrogenase (IDH) mutant grade 2 and 3 glioma (G2/3 gliomas).
Jun 06, 2023 10:31 pm ET
Day One Announces Pricing of Public Offering of Common Stock
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the pricing of its...
Jun 06, 2023 04:01 pm ET
Day One Announces Proposed Public Offering of Common Stock
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it has commenced...
Jun 04, 2023 12:45 pm ET
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical Company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
May 30, 2023 08:00 am ET
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management will participate...
May 25, 2023 08:30 pm ET
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
In a release issued under the same headline earlier today by Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), please note that in the second paragraph of the release and just below it, the oral session timing has changed. The corrected release...
May 25, 2023 05:00 pm ET
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the publication of three...
May 01, 2023 09:00 am ET
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2023...
Apr 26, 2023 09:31 am ET
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the acceptance of three...
Apr 12, 2023 08:00 am ET
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced an upcoming poster...
Mar 06, 2023 04:30 pm ET
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full...
Feb 27, 2023 08:00 am ET
Day One to Participate in the Cowen 43rd Annual Health Care Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management will participate...
Jan 09, 2023 07:30 am ET
Thinking about buying stock in Duck Creek Technologies, CureVac, Day One Biopharmaceuticals, Bed Bath & Beyond, or Ocugen?
NEW YORK, Jan. 9, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DCT, CVAC, DAWN, BBBY, and OCGN.
Jan 08, 2023 05:00 pm ET
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced positive topline results...
Dec 20, 2022 08:00 am ET
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender,...
Nov 17, 2022 07:00 am ET
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will...
Nov 11, 2022 07:00 am ET
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced two upcoming presentations...
Nov 07, 2022 04:30 pm ET
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced financial results for the...
Oct 17, 2022 08:00 am ET
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it has entered into a...
Sep 12, 2022 08:30 am ET
Day One Appoints Garry Nicholson as Chairman of the Board of Directors
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry...
Aug 04, 2022 04:30 pm ET
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced financial results for the...
Aug 02, 2022 08:00 am ET
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will...
Jun 21, 2022 08:30 am ET
Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the closing on June...
Jun 14, 2022 08:00 pm ET
Day One Announces Pricing of Upsized Public Offering of Common Stock
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the pricing of its...
Jun 14, 2022 07:30 am ET
Day One Announces Proposed Public Offering of Common Stock
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it has commenced...
Jun 13, 2022 08:30 am ET
Thinking about buying stock in Redbox, New Oriental Education, Day One Biopharmaceuticals, Exicure, or Oncternal Therapeutics?
NEW YORK, June 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RDBX, EDU, DAWN, XCUR, and ONCT.
Jun 12, 2022 05:00 pm ET
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced positive initial data from...
May 23, 2022 08:30 am ET
Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the first patients have been...
May 12, 2022 04:30 pm ET
Day One Reports First Quarter 2022 Financial Results and Provides Business Update
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced financial results for the...
Apr 06, 2022 08:30 am ET
Day One to Present at the 21st Annual Needham Virtual Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will present...
Mar 07, 2022 07:30 am ET
Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full...
Feb 28, 2022 04:05 pm ET
Day One to Participate in the Cowen 42nd Annual Health Care Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management will participate...
Jan 05, 2022 08:00 am ET
Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender,...
Nov 22, 2021 07:00 am ET
Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced that the first patient...
Nov 18, 2021 08:00 am ET
Day One to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that management will...
Nov 08, 2021 04:50 pm ET
Day One Reports Third Quarter 2021 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced financial results for...
Nov 03, 2021 08:00 am ET
Day One Announces Presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced an upcoming poster...
Sep 13, 2021 07:00 am ET
Day One Appoints Jaa Roberson as Chief People Officer
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced the appointment of Jaa...
Aug 17, 2021 07:00 am ET
Day One Appoints Scott Garland to Board of Directors
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced the appointment of Scott...
Aug 10, 2021 04:05 pm ET
Day One Reports Second Quarter 2021 Financial Results and Corporate Progress
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced financial results for...
Aug 04, 2021 08:00 am ET
Day One Biopharmaceuticals to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that Dr. Jeremy Bender,...
Jul 27, 2021 07:00 am ET
Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that the U.S. Food and...
Jun 21, 2021 07:00 am ET
Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced that the European Commission has...
Jun 01, 2021 04:01 pm ET
Day One Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the closing of its...
May 26, 2021 10:30 pm ET
Day One Announces Pricing of Upsized Initial Public Offering
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.